Pharma, Biotech and Generics Industry News | The Pharmaletter
网页Generics. 2 September 2024 German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. Generics.
Humanwell Healthcare and PuraCap to acquire Epic Pharma
网页2016年4月8日 · The China-based companies paid $550 million for 100% of Epic Pharma, which has 15 marketed products and a pipeline of 37 products. The acquisition will boost their presence and capabilities in the US generics market.
Pharmaceutical Industry News | The Pharmaletter
网页2024年8月20日 · Jazz Pharma raises $850 million through note offering. Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024.
Special Reports - The Pharma Letter
网页2020年6月17日 · Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji, an associate at Schiff Hardin LLP, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines. 4 …
Guy Martin - The Pharmaletter
网页2024年9月11日 · Guy Martin. Reporter The Pharma Letter. Guy Martin has been a journalist since 2008. He writes about all areas of pharma and biotech, and related business news. He has a special interest in emerging technologies leading to the development of personalized medicines, along with the changes this will bring to the pharmaceutical industry and beyond.
Innoskel | Biotechnology - The Pharmaletter
网页InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is spondyloepiphyseal dysplasia congenita, the second leading cause of dwarfism worldwide.
About The Pharma Letter | The Pharmaletter
网页3 天之前 · The Pharmaletter is a digital-only publication that covers the global pharmaceutical, biotech, generic and biosimilar industries. Founded in 1991, it offers news, analysis, data and trends on company, product, regulatory and market developments.
Positive top-line Phase II results for Soterios’ STS-01 in alopecia
网页31 May 2024. Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as a treatment for mild/moderate alopecia areata (AA). At 24 weeks, 75.9% of patients treated with once-daily topical dosing of 1% STS-01 met the primary efficacy endpoint (achieving >30% improvement in SALT ...
Pharma and Biotech News | The Pharmaletter
网页3 天之前 · Research shows migraine market to reach $16.4 billion by 2033. The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024. Biotechnology.
US FDA approves Idorsia’s once-daily Tryvio | The Pharmaletter
网页20 March 2024. The US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Tryvio was developed by Swiss drugmaker Idorsia (SIX: IDIA), whose shares were ...
跳至内容